Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted

Eligibility Criteria

• * Histologically and/or cytologically confirmed diagnosis of Stage I-III female breast cancer (including inflammatory breast cancer)
• * Scheduled to receive neoadjuvant/adjuvant HER2 targeted therapy
• * Between ≥18 years of age
• * Female patients of childbearing potential must have a negative pregnancy test (serum or urine) prior to enrollment. Female patients must agree to use effective barrier contraception during the period of therapy
• * Baseline LVEF ≥ 50%
• * Prior cancers allowed if no evidence of disease in last 5 years
• * ECOG 0-2
• * No prior history of treatment with HER2 targeted therapy or anthracyclines based chemotherapy
• * Adequate bone marrow function:
• * Adequate renal function, Creatinine \< 1.5x institutional ULN or calculated creatinine clearance ≥ 50 mL/min as estimated using the Cockcroft-Gault formula
• * Ability to understand the nature of this study protocol and give written informed consent
• * Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
• * Participants with stage IV breast cancer
• * Participants currently taking statins
• * Uncontrolled hypertension (systolic blood pressure \>190 mm Hg or diastolic blood pressure \>100 mm Hg)
• * No active liver disease
• * Current use of CYP 3A4 inhibitors
• * Any condition including the presence of laboratory abnormalities, which, in the opinion of the investigator places the subject at unacceptable risk if he/she were to participate in the study
• * Life expectancy \< 12 weeks
• * Pregnancy (positive pregnancy test) or lactation
• * Pre-existing sensory neuropathy \> grade one
• * Has significant cardiovascular disease, such as:
• * Major surgery without complete recovery in the past four weeks prior to screening
• * Concurrent active infection
• * Participant with uncontrolled and/ or active infection with HIV, Hepatitis B or Hepatitis C
• * Participant who has a history of allergy or hypersensitivity to any of the study drugs
• * Participant with a history of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, interstitial pulmonary fibrosis, pulmonary hypersensitivity pneumonitis
• * Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study